scholarly journals Editorial: progress towards a simple tool for screening for hepatic steatosis in the general population

2017 ◽  
Vol 46 (5) ◽  
pp. 559-560 ◽  
Author(s):  
J. Gallacher ◽  
S. McPherson
Keyword(s):  
General Population ◽  
Hepatic Steatosis ◽  
Simple Tool

scholarly journals The association of hepatic steatosis and fibrosis with heart failure and mortality

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Jiyun Park ◽  
Gyuri Kim ◽  
Hasung Kim ◽  
Jungkuk Lee ◽  
You-Bin Lee ◽  
...  
Keyword(s):  
Heart Failure ◽  
General Population ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Patient Group ◽  
Cox Regression ◽  
Nonalcoholic Fatty Liver ◽  
Fatty Liver Index ◽  
Increased Risk ◽  
All Cause Mortality

Abstract Background Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic disease and independently affects the development of cardiovascular (CV) disease. We investigated whether hepatic steatosis and/or fibrosis are associated with the development of incident heart failure (iHF), hospitalized HF (hHF), mortality, and CV death in both the general population and HF patients. Methods We analyzed 778,739 individuals without HF and 7445 patients with pre-existing HF aged 40 to 80 years who underwent a national health check-up from January 2009 to December 2012. The presence of hepatic steatosis and advanced hepatic fibrosis was determined using cutoff values for fatty liver index (FLI) and BARD score. We evaluated the association of FLI or BARD score with the development of iHF, hHF, mortality and CV death using multivariable-adjusted Cox regression models. Results A total of 28,524 (3.7%) individuals in the general population and 1422 (19.1%) pre-existing HF patients developed iHF and hHF respectively. In the multivariable-adjusted model, participants with an FLI ≥ 60 were at increased risk for iHF (hazard ratio [HR], 95% confidence interval [CI], 1.30, 1.24–1.36), hHF (HR 1.54, 95% CI 1.44–1.66), all-cause mortality (HR 1.62, 95% CI 1.54–1.70), and CV mortality (HR 1.41 95% CI 1.22–1.63) in the general population and hHF (HR 1.26, 95% CI 1.21–1.54) and all-cause mortality (HR 1.54 95% CI 1.24–1.92) in the HF patient group compared with an FLI < 20. Among participants with NAFLD, advanced liver fibrosis was associated with increased risk for iHF, hHF, and all-cause mortality in the general population and all-cause mortality and CV mortality in the HF patient group (all p < 0.05). Conclusion Hepatic steatosis and/or advanced fibrosis as assessed by FLI and BARD score was significantly associated with the risk of HF and mortality.

Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population

2016 ◽  
Vol 245 ◽  
pp. 123-131 ◽  
Author(s):  
Marcello Ricardo Paulista Markus ◽  
Peter J. Meffert ◽  
Sebastian Edgar Baumeister ◽  
Wolfgang Lieb ◽  
Ulrike Siewert ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
General Population ◽  
Hepatic Steatosis ◽  
Liver Enzyme

scholarly journals SAT-627 Racial and Ethnic Differences in Metabolic Disease in Obese Adolescents with Polycystic Ovary Syndrome

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Stanley Andrisse ◽  
Yesenia Garcia Reyes ◽  
Laura Pyle ◽  
Kristen Nadeau ◽  
Megan Moriarty Kelsey ◽  
...  
Keyword(s):  
Metabolic Disease ◽  
Insulin Resistance ◽  
General Population ◽  
Polycystic Ovary Syndrome ◽  
Hepatic Steatosis ◽  
Race And Ethnicity ◽  
Polycystic Ovary ◽  
Hispanic Youth ◽  
Ovary Syndrome ◽  
Metabolic Complications

Abstract Background: Polycystic ovary syndrome (PCOS) affects up to 15% of women and is associated with a multitude of metabolic complications including insulin resistance, type 2 diabetes, cardiovascular disease, and hepatic steatosis. In the general population, metabolic disease rates vary by race and ethnicity. The interaction of race and ethnicity with PCOS-related metabolic disease in adolescent youth has not been extensively examined. Methods: Secondary analysis of data from overweight and obese (&gt;90 BMI%ile) adolescent (12-21 years) female participants with PCOS enrolled across 4 protocols. Measurements included fasting hormone and metabolic measures, a 2-hour oral glucose tolerance test and MRI for hepatic fat. Groups were compared by ANOVA, with and without correction for BMI or chi-square tests for proportions. Results: Participants included 39 white (NHW 15.7±0.2 years; 97.7±0.2 BMI%ile), 50 Hispanic (15.2±0.3 years; 97.9±0.3 BMI%ile) and 12 black (NHB 16.0±0.6 years; 98.6±0.4 BMI%ile) adolescents. BMI%ile was different between groups (p=0.04), but age of menarche, free testosterone and hirsutism severity were not. Hepatic markers of insulin resistance were worse in Hispanic youth, including lower sex hormone binding globulin and TG/HDL ratio (p&lt;0.001), although HOMA-IR was worst in NHB (p=0.009) and Hispanic (p=0.036) compared to NHW youth. There were no significant differences in insulin concentrations—either fasting or during the OGTT—although fasting C-peptide was higher in Hispanic (p=0.008) compared to NHW youth. Fasting and 2-hour glucose concentrations were not different between groups. HbA1c was highest in NHB (5.7±0.4%, p&lt;0.001 vs. NHW, p=0.026 vs. Hispanic), then Hispanic (5.5±0.3, p&lt;0.001 vs. NHW), then NHW (5.2±0.3) youth. Fasting triglycerides differed between groups (p=0.029), being highest in Hispanic youth (129 [105,167] mg/dL). The frequency of hepatic steatosis (NHW 42%, Hispanic 62% NHB 25%, p=0.032) and the metabolic syndrome components HDL &lt;40 mg/dL (NHW 61%, Hispanic 82% NHB 50%, p&lt;0.001) and HbA1c 5.7-6.4% (NHW 5%, Hispanic 36% NHB 50%, p&lt;0.001) were different between the groups. Conclusions: Adolescents with PCOS appear to show similar racial and ethnic variation to the general population in terms of metabolic disease components.

scholarly journals Associations of liver volume and other markers of hepatic steatosis with all‐cause mortality in the general population

2021 ◽  
Author(s):  
Muhammad Naeem ◽  
Marcello Ricardo Paulista Markus ◽  
Mohammed Mousa ◽  
Sabine Schipf ◽  
Marcus Dörr ◽  
...  
Keyword(s):  
General Population ◽  
Hepatic Steatosis ◽  
Liver Volume ◽  
All Cause Mortality

scholarly journals Hepatic Steatosis Is Associated With Aortic Valve Sclerosis in the General Population

2013 ◽  
Vol 33 (7) ◽  
pp. 1690-1695 ◽  
Author(s):  
Marcello Ricardo Paulista Markus ◽  
Sebastian Edgar Baumeister ◽  
Jan Stritzke ◽  
Marcus Dörr ◽  
Henri Wallaschofski ◽  
...  
Keyword(s):  
Aortic Valve ◽  
General Population ◽  
Hepatic Steatosis ◽  
Aortic Valve Sclerosis

scholarly journals Magnetic Resonance Imaging of Diverticular Disease and its Association with Adipose Tissue Compartments and Constitutional Risk Factors in Subjects from a Western General Population

2020 ◽  
Vol 193 (01) ◽  
pp. 33-41
Author(s):  
Corinna Storz ◽  
Susanne Rospleszcz ◽  
Esther Askani ◽  
Theresa Rothenbacher ◽  
Jakob Linseisen ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Risk Factors ◽  
Adipose Tissue ◽  
Magnetic Resonance ◽  
General Population ◽  
Diverticular Disease ◽  
Hepatic Steatosis ◽  
Resonance Imaging ◽  
Metabolic Role ◽  
Tissue Compartments

Purpose To determine the association of asymptomatic diverticular disease as assessed by magnetic resonance imaging (MRI) with adipose tissue compartments, hepatic steatosis and constitutional risk factors within a cohort drawn from a Western general population. Materials and Methods Asymptomatic subjects enrolled in a prospective case-control study underwent a 3 Tesla MRI scan, including an isotropic VIBE-Dixon sequence of the entire trunk. The presence and extent of diverticular disease were categorized according to the number of diverticula in each colonic segment in a blinded fashion. The amount of visceral, subcutaneous, and total adipose tissue (VAT, SAT, and TAT) was quantified by MRI. Additionally, the degree of hepatic steatosis, indicated as hepatic proton density fat fraction (hepatic PDFF) was determined using a multi-echo T1w sequence. Constitutional cardiometabolic risk factors were obtained and univariate and multivariate associations were calculated. Results A total of 371 subjects were included in the analysis (58.2 % male, 56.2 ± 9.2 years). Based on MRI, 154 participants (41.5 %) had diverticular disease with 62 cases (17 %) being advanced diverticular disease. Subjects with advanced diverticular disease had a significantly higher body mass index (BMI) (BMI: 29.9 ± 5.1 vs. 27.5 ± 4.6, p < 0.001; respectively). Furthermore, all adipose tissue compartments were increased in subjects with advanced diverticular disease (e. g. VAT: 6.0 ± 2.8 vs. 4.2 ± 2.6 and SAT: 9.2 ± 3.6 vs. 7.8 ± 3.6, all p < 0.001, respectively). Similarly, subjects with advanced diverticular disease had significantly higher hepatic PDFF (4.9 [2.7, 11.4] vs. 6.1 [5.5, 14.6], p = 0.002). Conclusion Advanced diverticular disease is associated with an increased volume of adipose tissue compartments and BMI, which may suggest a metabolic role in disease development. Key Points: Citation Format

scholarly journals Effect of silibinin capsules combined with lifestyle modification on hepatic steatosis in patients with chronic hepatitis B

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Duo-Duo Lv ◽  
You-Juan Wang ◽  
Meng-Lan Wang ◽  
En-Qiang Chen ◽  
Ya-Chao Tao ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
General Population ◽  
Hepatitis B ◽  
Hepatic Steatosis ◽  
Chronic Hepatitis B ◽  
Lifestyle Modification ◽  
Transient Elastography ◽  
Lifestyle Changes ◽  
Relative Reduction

AbstractThe coexistence of HBV infection and hepatic steatosis is a novel characteristic of liver disease. Silibinin capsules (SC) is a silybin-phospholipid complex containing silybin as the bioactive component, which exerts a remarkable biological effect on various liver diseases, including nonalcoholic fatty liver disease (NAFLD). The purpose of this study was to investigate (1) the prevalence of hepatic steatosis in the general population and patients with chronic hepatitis B (CHB) and (2) to evaluate the effect of SC combined with therapeutic lifestyle changes (TLC) compared with TLC alone on hepatic steatosis in patients with CHB. A total of 16,451 individuals underwent transient elastography (TE) with the control attenuation parameter (CAP) measurement, among which the prevalence of hepatic steatosis was 31.1% in patients with CHB and 42.2% in the general population. The prevalence of hepatic steatosis differed between patients with CHB and the general population at an age of 40 years or older but was similar in individuals aged 39 years or younger (p < 0.05). Furthermore, in patients with CHB presenting hepatic steatosis, the post-6-month relative reduction in CAP in the SC combined with TLC group (p = 0.001) was significantly greater than in the TLC alone group (p = 0.183). The CAP distribution of different steatosis grades (S1, S2, and S3) in the SC combined with TLC group was decreased and S0 (CAP < 248 dB/m) increased significantly, but not significant in the TLC group. Thus, SC combined with TLC may effectively improve hepatic steatosis in patients with CHB.

Sign in / Sign up

Export Citation Format

Share Document